An investigation for investors in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares over potential securities laws violations by Sunesis Pharmaceuticals was announced and NASDAQ:SNSS stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 08/04/2015 --An investigation on behalf of investors of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares over potential securities laws violations by Sunesis Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) concerning whether a series of statements by Sunesis Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 23, 2015, Sunesis announced that the United States Food and Drug Administration will not approve its blood cancer drug Qinprezo based on available data, and that the Company must provide more clinical evidence supporting approval of Qinprezo. Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) declined to as low as $0.92 per share.

On July 31, 2015, NASDAQ:SNSS shares closed at $1.40 per share.

Those who purchased shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com